{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=79", "query": { "intervention": "serum sample", "page": 79 }, "page_size": 10 }, "pagination": { "page": 79, "page_size": 10, "total_count": 8381, "total_pages": 839, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=80&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=78&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-30T02:38:42.767Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01984359", "title": "HPV Serum DNA Levels Predicting Outcome in p16+ Squamous Cell Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Subjects With p16 Positive/HPV Positive Squamous Cell Carcinomas of the Oropharynx" ], "interventions": [ { "name": "Obtaining Human tissue", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Abramson Cancer Center at Penn Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2013-05", "completion_date": "2018-05-24", "has_results": false, "last_update_posted_date": "2020-04-10", "last_synced_at": "2026-10-30T02:38:42.767Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01984359" }, { "nct_id": "NCT03812562", "title": "Nivolumab and Yttrium-90 in Treating Patients With Liver Cancer Undergoing Surgical Resection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Hepatocellular Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Yttrium Y 90 Glass Microspheres", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "RADIATION" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2019-02-07", "completion_date": "2023-10-19", "has_results": false, "last_update_posted_date": "2024-02-21", "last_synced_at": "2026-10-30T02:38:42.767Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT03812562" }, { "nct_id": "NCT00048542", "title": "Study of Human Anti-TNF Monoclonal Antibody Adalimumab in Children With Polyarticular Juvenile Idiopathic Arthritis (JIA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Arthritis, Juvenile Idiopathic" ], "interventions": [ { "name": "Double-Blind Adalimumab/Placebo + MTX", "type": "BIOLOGICAL" }, { "name": "Double-Blind Adalimumab/Placebo", "type": "BIOLOGICAL" }, { "name": "OLE BSA Adalimumab +/- MTX", "type": "DRUG" }, { "name": "OLE FD Adalimumab +/- MTX", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "4 Years to 17 Years" }, "enrollment_count": 171, "start_date": "2002-09", "completion_date": "2010-06", "has_results": true, "last_update_posted_date": "2011-08-22", "last_synced_at": "2026-10-30T02:38:42.767Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Los Angeles, California • Stanford, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Delray Beach", "state": "Florida" }, { "city": "St. Petersburg", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00048542" }, { "nct_id": "NCT03044613", "title": "Nivolumab +/- Relatlimab Prior to Chemoradiation With II/III Gastro/Esophageal Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastric Cancer", "Esophageal Cancer", "GastroEsophageal Cancer" ], "interventions": [ { "name": "Nivolumab", "type": "DRUG" }, { "name": "Relatlimab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2017-07-11", "completion_date": "2027-08", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-10-30T02:38:42.767Z", "location_count": 3, "location_summary": "Baltimore, Maryland • Pittsburgh, Pennsylvania • Dallas, Texas", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03044613" }, { "nct_id": "NCT03647423", "title": "QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Chordoma", "Unresectable Malignant Neoplasm" ], "interventions": [ { "name": "Aldoxorubicin Hydrochloride", "type": "BIOLOGICAL" }, { "name": "ALT-803", "type": "BIOLOGICAL" }, { "name": "ETBX-051", "type": "BIOLOGICAL" }, { "name": "ETBX-061", "type": "BIOLOGICAL" }, { "name": "GI-6301", "type": "BIOLOGICAL" }, { "name": "haNK", "type": "BIOLOGICAL" }, { "name": "Avelumab", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "SBRT", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2018-08-31", "completion_date": "2021-12-28", "has_results": false, "last_update_posted_date": "2025-02-21", "last_synced_at": "2026-10-30T02:38:42.767Z", "location_count": 1, "location_summary": "El Segundo, California", "locations": [ { "city": "El Segundo", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03647423" }, { "nct_id": "NCT04192773", "title": "An fMRI Investigation of the Effects of IV Lidocaine on Tinnitus", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Tinnitus" ], "interventions": [ { "name": "IV Lidocaine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "D. Bradley Welling, MD, PhD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2021-04-28", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2025-12-02", "last_synced_at": "2026-10-30T02:38:42.767Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04192773" }, { "nct_id": "NCT00413959", "title": "VELCADE,Rituximab,Cyclophosphamide and Decadron", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Non-Hodgkin", "Lymphoma, B-Cell" ], "interventions": [ { "name": "VELCADE®", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Decadron", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oncology Specialists, S.C.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 12, "start_date": "2006-08", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2018-09-19", "last_synced_at": "2026-10-30T02:38:42.767Z", "location_count": 2, "location_summary": "Niles, Illinois • Park Ridge, Illinois", "locations": [ { "city": "Niles", "state": "Illinois" }, { "city": "Park Ridge", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00413959" }, { "nct_id": "NCT01616680", "title": "Brentuximab Vedotin in Treating Patients With Steroid-Resistant Acute Graft-Versus-Host Disease", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Graft Versus Host Disease" ], "interventions": [ { "name": "brentuximab vedotin", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 0, "start_date": "2012-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-27", "last_synced_at": "2026-10-30T02:38:42.767Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01616680" }, { "nct_id": "NCT06532279", "title": "Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Head and Neck Squamous Cell Carcinoma", "Hypopharyngeal Squamous Cell Carcinoma", "Laryngeal Squamous Cell Carcinoma", "Nasopharyngeal Squamous Cell Carcinoma", "Oral Cavity Squamous Cell Carcinoma", "Oropharyngeal Squamous Cell Carcinoma", "Stage 0 Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage 0 Hypopharyngeal Carcinoma AJCC v8", "Stage 0 Nasopharyngeal Carcinoma AJCC v8", "Stage 0 Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage I Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage I Hypopharyngeal Carcinoma AJCC v8", "Stage I Laryngeal Cancer AJCC v8", "Stage I Lip and Oral Cavity Cancer AJCC v8", "Stage I Nasopharyngeal Carcinoma AJCC v8", "Stage I Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage II Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage II Hypopharyngeal Carcinoma AJCC v8", "Stage II Laryngeal Cancer AJCC v8", "Stage II Lip and Oral Cavity Cancer AJCC v8", "Stage II Nasopharyngeal Carcinoma AJCC v8", "Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8", "Stage III Hypopharyngeal Carcinoma AJCC v8", "Stage III Laryngeal Cancer AJCC v8", "Stage III Lip and Oral Cavity Cancer AJCC v8", "Stage III Nasopharyngeal Carcinoma AJCC v8", "Stage III Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVA Hypopharyngeal Carcinoma AJCC v8", "Stage IVA Laryngeal Cancer AJCC v8", "Stage IVA Lip and Oral Cavity Cancer AJCC v8", "Stage IVA Nasopharyngeal Carcinoma AJCC v8", "Stage IVA Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stage IVB Hypopharyngeal Carcinoma AJCC v8", "Stage IVB Laryngeal Cancer AJCC v8", "Stage IVB Lip and Oral Cavity Cancer AJCC v8", "Stage IVB Oropharyngeal (p16-Negative) Carcinoma AJCC v8", "Stomatitis" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Image Guided Radiation Therapy", "type": "RADIATION" }, { "name": "Intensity-Modulated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "MnSOD Mimetic BMX-001", "type": "DRUG" }, { "name": "Placebo Administration", "type": "DRUG" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "PROCEDURE", "DRUG", "RADIATION" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2025-06-23", "completion_date": "2032-01-01", "has_results": false, "last_update_posted_date": "2026-08-17", "last_synced_at": "2026-10-30T02:38:42.767Z", "location_count": 153, "location_summary": "Gilbert, Arizona • Peoria, Arizona • Phoenix, Arizona + 126 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Surprise", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06532279" }, { "nct_id": "NCT00217386", "title": "Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "etanercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2004-03", "completion_date": null, "has_results": false, "last_update_posted_date": "2010-09-15", "last_synced_at": "2026-10-30T02:38:42.767Z", "location_count": 4, "location_summary": "Bellingham, Washington • Port Angeles, Washington • Seattle, Washington", "locations": [ { "city": "Bellingham", "state": "Washington" }, { "city": "Port Angeles", "state": "Washington" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00217386" } ] }